But retatrutide adds GIP to an already powerful cocktail
For patients with type 2 diabetes or obesity, tirzepatide represents a well-studied, FDA-approved medication with demonstrated efficacy in clinical trials
When the wrong stuff takes over stubborn fat, blood sugar spikes, out-of-control cravings your whole system feels it
Algunos tambin estn aprobados para el manejo crnico del peso en personas con obesidad (IMC 30 kg/m) o sobrepeso (IMC 27 kg/m) con al menos una comorbilidad relacionada con el peso
The rationale for adding glucagon receptor agonism centres on energy expenditure
2,3 Furthermore, several cardiovascular outcome trials (CVOT) suggest GLP-1 RAs confer a mortality benefit, with significant reductions in major adverse cardiovascular events, all-cause mortality, heart failure severity, and worsening kidney function